GILEAD SCIENCES, INC. Long-Term Debt, Maturity, Year Five
GILEAD SCIENCES, INC. (GILD) had Long-Term Debt, Maturity, Year Five of $1.75 billion as of 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2021-02-25
- 2020-12-31: Long-Term Debt, Maturity, Year Five $1.75B.
- 2019-12-31: Long-Term Debt, Maturity, Year Five $1.75B.
- 2018-12-31: Long-Term Debt, Maturity, Year Five $750.00M.
- 2017-12-31: Long-Term Debt, Maturity, Year Five $3.44B.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2020-12-31 | $1.75B 10-K · filed 2021-02-25 |
| 2019-12-31 | $1.75B 10-K · filed 2020-02-25 |
| 2018-12-31 | $750.00M 10-K · filed 2019-02-26 |
| 2017-12-31 | $3.44B 10-K · filed 2018-02-27 |
| 2016-12-31 | $2.25B 10-K · filed 2017-02-27 |
| 2015-12-31 | $2.50B 10-K · filed 2016-02-24 |
| 2014-12-31 | $500.00M 10-K · filed 2015-02-25 |
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |